Guan Zhenqi, Jiao Shiming, Yang Xingxing, Liu Shengcong, Li Wenting, Yu Le, Qu Jia, Zhou Xiangtian, Pan Miaozhen
State Key Laboratory of Eye Health, Oujiang Laboratory, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Research Unit of Myopia Basic Research and Clinical Prevention and Control, Chinese Academy of Medical Sciences (2019RU025), Wenzhou, Zhejiang, China.
Invest Ophthalmol Vis Sci. 2025 May 1;66(5):46. doi: 10.1167/iovs.66.5.46.
Myopia is a common refractive error that is emerging as a major concern worldwide, because it is not clear how best to treat it. To improve therapeutic management of this condition, novel favorable risk-benefit profiles and accessible approaches are urgently needed. Here, we evaluate the efficacy of bendazac L-lysine (BDL) for attenuating experimental myopia in guinea pigs.
Three-week-old pigmented guinea pigs wore occluders or -4.00 diopter (D) lenses on the right eye to induce either form-deprivation myopia (FDM) or lens-induced myopia (LIM), respectively. Simultaneously, (1) induced-myopic eyes received daily peribulbar injections of the aldose reductase inhibitors (ARIs) sorbinil, zopolrestat, or BDL during FDM or LIM. (2) FDM eyes received daily peribulbar injections of one of four doses of BDL, or twice-daily BDL eye drops or ointment. (3) FDM eyes received daily peribulbar injections of either bendazac or L-lysine. (4) Guinea pigs that were not subjected to myopia induction (normal vision) received daily peribulbar injections of BDL. The effects on refraction, axial length, and choroidal thickness (ChT) were measured after treatment.
Sorbinil and zopolrestat had no effect on FDM, whereas BDL inhibited FDM and LIM development. BDL treatment, regardless of peribulbar injection, eye drops, or ointment, suppressed FDM. Bendazac, rather than L-lysine, is the active ingredient in BDL. The BDL significantly inhibited either FDM or LIM associated decrease in ChT, without altering ChT during normal ocular growth.
BDL significantly suppressed myopia development in experimentally induced myopia in guinea pigs. This study suggests that BDL may be a viable candidate for myopia control.
近视是一种常见的屈光不正，正成为全球主要关注的问题，因为目前尚不清楚如何进行最佳治疗。为了改善这种疾病的治疗管理，迫切需要新的有利的风险效益概况和可行的方法。在此，我们评估苄达赖氨酸（BDL）减轻豚鼠实验性近视的疗效。
三周龄的有色豚鼠右眼佩戴眼罩或-4.00屈光度（D）镜片，分别诱导形觉剥夺性近视（FDM）或透镜诱导性近视（LIM）。同时，（1）诱导近视的眼睛在FDM或LIM期间每天球周注射醛糖还原酶抑制剂（ARIs）索比尼尔、唑泊司他或BDL。（2）FDM眼睛每天球周注射四种剂量之一的BDL，或每日两次BDL滴眼液或眼膏。（3）FDM眼睛每天球周注射苄达酸或L-赖氨酸。（4）未进行近视诱导（视力正常）的豚鼠每天球周注射BDL。治疗后测量对屈光、眼轴长度和脉络膜厚度（ChT）的影响。
索比尼尔和唑泊司他对FDM无影响，而BDL可抑制FDM和LIM的发展。BDL治疗，无论采用球周注射、滴眼液还是眼膏，均能抑制FDM。苄达酸而非L-赖氨酸是BDL中的活性成分。BDL显著抑制FDM或LIM相关的ChT降低，而在正常眼部生长过程中不改变ChT。
BDL显著抑制豚鼠实验性近视的近视发展。本研究表明BDL可能是一种可行的近视控制候选药物。
